University of California San Francisco
Give to UCSF
COVID vaccine efficacy varied by age, BMI, sex, and smoking status, with levels changing over six months in a UCSF-led study. Pfizer and Moderna had higher antibody responses than Johnson & Johnson at one month, but Johnson & Johnson overtook them at six months.
A hepatitis outbreak in children occurred after COVID-19 lockdowns eased in 2022. Sudden exposure to a multitude of viruses upon reopening may have triggered this response in a small group of children.
Thermo Fisher Scientific Inc. and UCSF will accelerate advanced cell therapies for difficult to treat conditions like cancer from a new manufacturing facility.
A clinical trial showed that, rather than removing lymph nodes, leaving them intact could help immunotherapy activate tumor-fighting T cells in the lymph nodes.
Respiratory viral infections pose significant morbidity and mortality to patients with chronic lung diseases like emphysema and COPD, causing exacerbations that drive destruction of normal lung tissue
UCSF researchers found that distributing pro-COVID-19 vaccine information in EDs in English and Spanish increased vaccine acceptance, especially among Latinos and those without primary care physicians.
Balyn Zaro’s lab investigates the cause and consequence of genetic diversity in the immune system, in hopes that her discoveries can lead to better treatments for all patients.
When we inhale an airborne virus, our lung cells take on the role of immune system first responders. Catera Wilder, PhD, studies the molecular details of this response and how it can go awry, causing the body to damage its own tissue and cells.
Angela Phillips, PhD, leads research that could help predict future viruses like COVID and the antibodies we might use to treat them.
Emily Goldberg's lab studies what happens during aging to a particular set of immune cells: those embedded in fat tissue. She hypothesizes that changes to these cells during aging could be key to age-related inflammation.
